Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants
Outlook Therapeutics, Inc. received U.S. clearance for Lytenava on Friday. Trading in its shares was paused following the news.
Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms
Outlook Therapeutics, Inc. stock surged Tuesday after the company said the U.S. Food and Drug Administration accepted its resubmitted Biologics License Application, or BLA, for ONS-5010/LYTENAVA as a treatment for wet age-related macular degeneration. A BLA is the FDA application used to seek approval to market a biologic medicine. OTLK traded at $1.51, up about 30.2% from its previous close of $1.16, with intraday volume above 33.7 million shares, according to market data available in afternoon trading.
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Outlook Therapeutics, Inc. shares fell sharply in after-hours trading on Dec. 31 after the U.S. Food and Drug Administration again declined to approve its ONS-5010/LYTENAVA filing for wet age-related macular degeneration. The stock closed down 15.51% at $1.58 and slid to $0.58 after hours. Nasdaq
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision
Outlook Therapeutics, Inc. shares closed Monday up 8.8% at $1.98 after trading between $1.78 and $1.98. The stock was last up about 2% at $2.02 in late after-hours trading, with about 5.7 million shares changing hands. StockAnalysis
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date
Outlook Therapeutics shares jumped today after the U.S. FDA accepted the company’s resubmitted Biologics License Application for ONS‑5010/LYTENAVA, its bevacizumab-based eye drug for wet AMD, and set a PDUFA review date of December 31, 2025. Here’s what investors need to know.
TechStock² Updates
